Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID-19 severe or critically

	COVID-19 prophylaxis (excluding children)
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	COV005 AstraZeneca phase 3 US ... ComFluCOV ... Valim AstraZeneca Oxford pooled analysis ... Bonelli John Com-COV2 Kanokudom AstraZeneca phase 3 US ... Asano Folegatti Com-COV ChAdOx1 phase 3 ...

17 studies excluded by filtering options 1

6664	Scotland cohort, 0	1	10	0		not a RCT	risk of bias not avaialble
6965	Bernal (PHE, 19th February 2021), 2021	1	13	0		not a RCT	risk of bias not avaialble
6975	Corchado-Garcia, 2021	0	13	0	selection pending
7012	Pottegard, 2021	1	15	4		not a RCT	high risk of bias
7022	Bernal, 0	1	13	0		not a RCT	risk of bias not avaialble
8252	Edward (Vaxzevria), 2021	1	13	4		not a RCT	high risk of bias
8267	Burn (Vaxzevria), 2021	1	13	4		not a RCT	high risk of bias
9070	Tobaiqy M, 2021	2	32	0	excluded	not a RCT	risk of bias not avaialble
9216	Sultan, 2022	0	12	0	selection pending
9268	Nguyen, 2021	0	11	0	selection pending
9296	Hippisley-Cox, 2021	1	12	0		not a RCT	risk of bias not avaialble
9297	Simpson (ChAdOx1), 2021	1	12	0		not a RCT	risk of bias not avaialble
9313	EPIPHARE (Vaxzevria), 2022	1	12	0		not a RCT	risk of bias not avaialble
9360	Husby (Astra), 2021	1	12	0		not a RCT	risk of bias not avaialble
9467	Clemens, 2021	0	10	0	selection pending
9492	Patone, 2021	1	12	0		not a RCT	risk of bias not avaialble
9614	Rearte, 2022	0	12	0	selection pending